A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations
CIDH305X2101
Phase 1 other active
Quick answer
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations for Advanced malignancies that harbor IDH1R132 mutations is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advanced malignancies that harbor IDH1R132 mutations
- Phase
- Phase 1
- Modality
- other
- Status
- active